Greetings HHSE Shareholders, friends and followers - Over

New Post Public Reply Private Reply Replies (0) Message Board
Nkerimi
696
Greetings HHSE Shareholders, friends and followers - Over the past few weeks we have been collecting questions received from shareholders, and will address these in this weekend's blog below.

1). Q: REGARDING THE FORM 10-FILING DATE, WILL YOU TELL SHAREHOLDERS "IN ADVANCE?"

A: No. We have been advised that specific disclosure or telegraphing of the date that the company will be filing the Form 10 Registration Statement with the S.E.C. would create stock-trading advantages that might result in S.E.C. "comments" or potentially a rejection of the company's registration.

2). Q: IS THE COMPANY "ON TRACK" FOR THE COMPLETION OF THE FORM 10 FILING IN A TIMELY MANNER?

A: Yes.

3). HOW WILL THE FILING OF THE FORM 10 DIRECTLY BENEFIT THE COMPANY'S OPERATIONS?

A: The benefits of becoming a fully-reporting / fully-registered equity are not entirely "direct" for the issuer - in that the registration filing primarily benefits SHAREHOLDERS through improved daily share volume (which often leads to a higher PPS). The company is more likely to benefit from the near-simultaneous filing of the S-1 Registration, which will enable HHSE to directly receive operational and growth funding from the sale of new stock shares.

4). WILL THE COMPANY NEED TO RESOLVE OR SETTLE THE VARIOUS RECENT LITIGATION MATTERS BEFORE FILING THE FORM 10?

A: No. The values of the company's various assets and liabilities - regardless of dollar amount or form - only need to be DISCLOSED to the auditors and within the financials and narrative text of the registration statement. A company can have any number of disputes, debts or significant liabilities, as long as they are disclosed and noted.

5). WITHOUT JEOPARDIZING THE COMPANY'S LEGAL STRATEGIES, CAN YOU ELABORATE ON THE LEVEL OF RISK OR CONCERN THAT MANAGEMENT HAS FOR SOME OF THE MORE SIGNIFICANT LEGAL ISSUES?

A: Yes. Management has identified each of the legal matters that involve the appearance or potential of liability, specifically and alphabetically: (1) Bedrock Ventures, (2) Crimson Forest, (3) Interstar Releasing, (4) JSJ Financial, (5) Lewin / East-Side Story, (6) O'Brien Films, (7) Origin Releasing and (8) Uptone Pictures. Items 1 and 4 are foreign defaults that qualify for adjudication under Arkansas Law (and based upon the nature of these notes, Arkansas law is expected to result in a dismissal); Item 2 is ongoing, including a HHSE counterclaim for $4-mm; Item 3 is a California Judgment that was obtained as the result of two fraudulent misrepresentation by the Plaintiff to the California Court; accordingly, under Arkansas law, this case can be dismissed; Items 5 and 6 are foreign defaults based upon non-existent deals (i.e., Plaintiffs filed lawsuits against HHSE without having an actual contractual basis), and as such, these can be dismissed under Arkansas law; Item 7 is a judgment which was voluntarily entered into by HHSE, but newly obtained documents show that the HHSE was induced into accepting the judgment based on an agreement that had been modified by the Plaintiffs; accordingly, this provides the basis to either re-open the case in Texas or to dismiss it under Arkansas Law. Item 8 is being handled by HHSE's California counsel and the company is informed that there is an expectation that this dispute will be dismissed soon. The specific status of each of these disputes or matters is described in clear detail within the Form 10 narrative. Management believes that current legal strategies will result in a positive outcome for HHSE and that we do not feel a material threat to the company's ongoing operations or current activities.

6). ARE PRODUCER LAWSUITS AGAINST DISTRIBUTORS COMMON, OR IS THIS REPRESENTATIVE OF "SOMETHING UNIQUE" TO HHSE?

A: Unfortunately, in the "independent producer" community, lawsuits against distributors are extremely common. Producers often raise the money for a movie by providing investors with inflated expectations of a film's potential performance... and when the "reality of the marketplace" is delivered, they feel pressure to blame it on the distributor. When HHSE suspects this has occurred, we will often move to quickly "unscramble the egg" and divorce ourselves from proceeding with that particular project. In any event, some media distribution companies are not as cautious and have an extremely high rate of litigation (up to 50% of titles released end up in litigation). While HHSE wishes that none of the company's program suppliers would ever be unhappy, we are somewhat relieved to recognize that our dispute frequency is way below average for the industry. Based upon management's research of legal disputes for independent distributors, HHSE appears to have the second lowest levels both in terms of total number of cases and the percentage of releases that end up in litigation disputes (18 titles out of 454 releases). Management feels that the new business model for HHSE and MyFlix will result in a far lower frequency of producer disputes for several reasons which are elaborated on in the Form 10 narrative.

7). WHAT'S HAPPENING WITH MyFlix? CAN YOU ELABORATE ON THE DATE THAT THIS STREAMING SERVICE AND O.T.T. SITE WILL "GO LIVE"?

A: An Update on MYFLIX will be provided as a separate blog this week. It's exciting, moving quickly and is poised for a successful launch.

8). THERE SEEMS TO BE LOT OF MISINFORMATION AND SKEPTICISM ABOUT HHSE ON THE "I-HUB" CHAT BOARD WHICH IS CONCERNING TO SOME SHAREHOLDERS. HOW CAN YOU RESPOND TO THESE ATTACKS?

A: Ignore the short-sellers and price manipulators that use misinformation, hidden identities and "mumbo-jumbo" terminology to try to negatively impact the perception of HHSE to our legitimate shareholders. Consider the source: these are the same folks that every few months declare that "the sky is falling" and that "ooooh, if only you knew the secrets that I know, you'd sell your shares to us CHEAP, and RIGHT NOW!" How many times have these I-Hub trolls incorrectly predicted the "imminent demise" of HHSE due to some easily resolved legal dispute or fabricated false claim (e.g.,there's a huge judgment they can't set-aside, Fred is a domestic terrorist, Parkinson has nice hair)... and then BRAGGED that their strategy is to "rinse and repeat" their daily PPS pricing manipulation with small dollar (uneconomical) trades to the bid? Their predictions of doom have always been proven wrong. After all, it only takes a few thousand dollars of buyer-bid support to crush these PPS boxing efforts... which is why the filing of the HHSE Form 10 poses an existential threat to the I-Hub trolls (in that the volume of NEW shareholders in HHSE - post-filing - will reduce their effectiveness to that of mumbling hobos in a large crowd of legitimate traders).

9). WHAT ARE THE NEXT NEW RELEASE TITLES FOR HHSE / MEDALLION? DO YOU HAVE ANY "BIG" RELEASES YET?

A: Yes, we have several big, new projects in the works for release early in 2019 - titles that are significantly higher in stature (and theatrical release breadth) than any prior HHSE / Medallion releases. However, this Q&A blog is not the right forum and moment to disclose these important developments.

10). IS HHSE CONSIDERING ANY "NON FILM" ACQUISITIONS WITH THE PROCEEDS FROM THE S-1 REGISTRATION?

A: Yes, the company is looking at several "related business opportunities" that would be a complement to HHSE / Medallion, but not specifically falling in the existing operational categories. At present, there are three cash-flow positive / profitable businesses that could be acquired by HHSE following the S-1 revenues which may be of merit to the diversification and expansion of the company. However, it would be detrimental to the negotiating process to prematurely begin public discussion / disclosure of new business opportunities that are still in the pre-documentation discussion and research stages.

MORE TO FOLLOW>>>>








Hannover House Inc. (HHSE) Stock Research Links

HHSE Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Rigel Pharmaceuticals Updates on Financials and Future Plans

Updated Category News Views 130

Rigel Pharmaceuticals' Business Update and 2025 Outlook Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a notable biotechnology company, recently provided a compelling business update, highlighting its financial performance and strategic ambitions for 2025. The report shared preliminary insights into the fourth quarter of 2024, showcasing substantial revenue streams from its...

Continue Reading
Grant Cardone Explores Future of Investments in Bitcoin and Real Estate

Updated Category News Views 409

Understanding Investment Shifts in Today's Economy Grant Cardone, a prominent real estate investor and entrepreneur known for his work with Cardone Capital, is keeping a keen eye on the fluctuations within the investment landscape. With approximately $7 trillion currently held in money markets, he questions where this substantial amount of cash will be allocated as...

Continue Reading
BlueNord ASA Secures Major Funding Through Hybrid Bond Issuance

Updated Category News Views 175

BlueNord ASA Successfully Places Hybrid Bond Issue BlueNord ASA (OSE: BNOR) has achieved a significant milestone in its financial strategy with the successful placement of a new subordinated callable hybrid bond issue worth USD 300 million. This bond matures in 2085, marking a robust step forward for the company. The first call on the hybrid bond is at 100% of nominal...

Continue Reading
Aehr Test Systems (NASDAQ: AEHR) Sees Growth in 2026 Amid Fluctuations

Updated Category News Views 133

Strong Start to 2026 for Aehr Test Systems For shares of Aehr Test Systems, the year 2026 has kicked off in a remarkable way. As of the latest market close, the stock has risen by 44%, showcasing significant investor enthusiasm. This surge follows a recent earnings release that, while presenting mixed signals, ultimately contributed to a 16% jump in the stock price the...

Continue Reading
Carlton Precious Enhances Community Relations and Expansion Plans

Updated Category News Views 151

Carlton Precious Inc. Strengthens Community Engagement TORONTO — Carlton Precious Inc. (TSX-V: CPI | OTCQB: NBRFF), a notable player in precious and base metals exploration, is excited to share significant developments regarding its Esquilache Silver project. The Company has successfully finalized an agreement with the local community of San Antonio de Esquilache, which...

Continue Reading